Sign in to view content

Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID

W. Lloyd Clark, MD, FASRS

Video
Published 2021

Related

New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2022
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more